Related references
Note: Only part of the references are listed.Modeling the Ruminant Placenta-Pathogen Interactions in Apicomplexan Parasites: Current and Future Perspectives
Ivan Pastor-Fernandez et al.
FRONTIERS IN VETERINARY SCIENCE (2021)
Endochin-like quinolones (ELQs) and bumped kinase inhibitors (BKIs): Synergistic and additive effects of combined treatments against Neospora caninum infection in vitro and in vivo
Nicoleta Anghel et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2021)
Outbreaks of clinical toxoplasmosis in humans: five decades of personal experience, perspectives and lessons learned
Jitender P. Dubey
PARASITES & VECTORS (2021)
In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts
Dennis Imhof et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2021)
Neosporosis, Toxoplasmosis, and Sarcocystosis in Ruminants: An Update
David S. Lindsay et al.
VETERINARY CLINICS OF NORTH AMERICA-FOOD ANIMAL PRACTICE (2020)
Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis-A Short Bridge between Two Distant Illnesses
Alina Secrieru et al.
MOLECULES (2020)
Neospora caninum: Structure and Fate of Multinucleated Complexes Induced by the Bumped Kinase Inhibitor BKI-1294
Pablo Winzer et al.
PATHOGENS (2020)
Orally Bioavailable Endochin-Like Quinolone Carbonate Ester Prodrug Reduces Toxoplasma gondii Brain Cysts
J. Stone Doggett et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Efficacy of Guanabenz Combination Therapy against Chronic Toxoplasmosis across Multiple Mouse Strains
Jennifer Martynowicz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
The Impact of BKI-1294 Therapy in Mice Infected With the Apicomplexan Parasite Neospora caninum and Re-infected During Pregnancy
Pablo Winzer et al.
FRONTIERS IN VETERINARY SCIENCE (2020)
Isolation, Genotyping, and Mouse Virulence Characterization of Toxoplasma gondii From Free Ranging Iberian Pigs
Mercedes Fernandez-Escobar et al.
FRONTIERS IN VETERINARY SCIENCE (2020)
In vitro treatment of Besnoitia besnoiti with the naphto-quinone buparvaquone results in marked inhibition of tachyzoite proliferation, mitochondrial alterations and rapid adaptation of tachyzoites to increased drug concentrations
Joachim Mueller et al.
PARASITOLOGY (2019)
Disease Tolerance in Toxoplasma Infection
Stephanie J. Melchor et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2019)
Virulence in Mice of a Toxoplasma gondii Type II Isolate Does Not Correlate With the Outcome of Experimental Infection in Pregnant Sheep
Roberto Sanchez-Sanchez et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2019)
Toxoplasmosis: Overview from a One Health perspective
Olgica Djurkovic-Djakovic et al.
FOOD AND WATERBORNE PARASITOLOGY (2019)
Repurposing of commercially available anti-coccidials identifies diclazuril and decoquinate as potential therapeutic candidates against Besnoitia besnoiti infection
Alejandro Jimenez-Melendez et al.
VETERINARY PARASITOLOGY (2018)
Treatment of Toxoplasmosis and Neosporosis in Farm Ruminants: State of Knowledge and Future Trends
Roberto Sanchez-Sanchez et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
Accessible and distinct decoquinate derivatives active against Mycobacterium tuberculosis and apicomplexan parasites
Richard M. Beteck et al.
COMMUNICATIONS CHEMISTRY (2018)
In vitro screening of the open source Pathogen Box identifies novel compounds with profound activities against Neospora caninum
Joachim Mueller et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2017)
Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis
Joachim Mueller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Drugs in development for toxoplasmosis: advances, challenges, and current status
P. Holland Alday et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity
Madalyn M. McFarland et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria
Allison M. Stickles et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria
Galen P. Miley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum
Pablo Winzer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans
Hai-Xia Wei et al.
PLOS ONE (2015)
Orally Bioavailable 6-Chloro-7-methoxy-4(1H)-quinolones Efficacious against Multiple Stages of Plasmodium
R. Matthew Cross et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Recent progress in the development of anti-malarial quinolones
Richard M. Beteck et al.
MALARIA JOURNAL (2014)
Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice
Hongxing Wang et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2014)
Drug repurposing and human parasitic protozoan diseases
Katherine T. Andrews et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2014)
Efficacy of decoquinate against Sarcocystis neurona in cell cultures
David S. Lindsay et al.
VETERINARY PARASITOLOGY (2013)
Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial Drug
Filipa P. da Cruz et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
The adaptive potential of a survival artist: characterization of the in vitro interactions of Toxoplasma gondii tachyzoites with di-cationic compounds in human fibroblast cell cultures
Christian Kropf et al.
PARASITOLOGY (2012)
Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis
J. Stone Doggett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Point mutations in the Theileria annulata cytochrome b gene is associated with buparvaquone treatment failure
Hassan Sharifiyazdi et al.
VETERINARY PARASITOLOGY (2012)
A Chemical Genomic Analysis of Decoquinate, a Plasmodium falciparum Cytochrome b Inhibitor
Tae-gyu Nam et al.
ACS CHEMICAL BIOLOGY (2011)
Teratogenic mechanisms of medical drugs
Marleen M. H. J. van Gelder et al.
HUMAN REPRODUCTION UPDATE (2010)
Oral pharmacokinetics and milk residues of decoquinate in milking cows
J. Quintero-de Leonardo et al.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS (2009)
The role of ATP-binding cassette (ABC) proteins in protozoan parasites
Virginie Sauvage et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2009)
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone
Pascale Meneceur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
The quinolones: Past, present, and future
VT Andriole
CLINICAL INFECTIOUS DISEASES (2005)
Real-time PCR for diagnosis and follow-up of toxoplasma reactivation after allogeneic stem cell transplantation using fluorescence resonance energy transfer hybridization probes
JM Costa et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2000)
Activity of decoquinate against Cryptosporidium parvum in cell cultures and neonatal mice
DS Lindsay et al.
VETERINARY PARASITOLOGY (2000)
Share Paper
